Relmada Therapeutics to Participate in Wells Fargo Healthcare Conference

CORAL GABLES, Fla., Sept. 01, 2026 /CourierPR/ -- Relmada Therapeutics, a clinical-stage biotechnology firm working on innovative treatments for oncology and central nervous system disorders, will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference. The event, set to take place in Boston from September 8 to 10, 2026, will feature one-on-one meetings between senior management of Relmada and potential investors.

During the conference, Relmada's executives will engage in private discussions with attendees, aiming to discuss the company's progress and future plans for its lead candidates, NDV-01 and sepranolone. These drugs are currently in clinical development and hold the potential to address significant unmet medical needs in oncology and CNS conditions.

For those interested in scheduling a meeting with Relmada's management team, contact your Wells Fargo representative. The conference will offer a unique opportunity for investors to gain insights into the company's pipeline and strategic direction.

Relmada Therapeutics, based on its ongoing clinical trials and advancements, continues to position itself as a leader in biotechnology innovation. The company’s focus on developing transformative therapies for serious medical conditions underscores its commitment to advancing patient care.